Trial Profile
A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- 13 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 02 Aug 2022 Planned End Date changed from 1 Jun 2022 to 31 Dec 2022.
- 03 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jan 2022.